Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules

Pemetrexed, a new multitarget antifolate antineoplastic agent, has significantly improved the overall survival in nonsquamous non-small-cell lung cancer patients. Presently, pemetrexed is recommended for first line treatment in combination with platinum derivatives, for second line treatment as a si...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xin, Wei, Sen, Chen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057332/
https://www.ncbi.nlm.nih.gov/pubmed/24944517
http://dx.doi.org/10.2147/OTT.S45148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057332/
https://www.ncbi.nlm.nih.gov/pubmed/24944517
http://dx.doi.org/10.2147/OTT.S45148

Ejemplares similares